Dialysis Chain News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NephroPlus, India's largest dialysis chain, has secured $103 million (₹860 crore) in a Series F funding round led by Quadria Capital. This funding, a mix of fresh capital and a secondary sale, aims to drive expansion plans within India and targeted markets overseas. The primary component of the funding is ₹100 crore. Quadria Capital will become a minority shareholder, valuing NephroPlus at over ₹2,000 crore. Existing investors like Bessemer Venture Partners, International Finance Corporation, and IIFL also participated in the funding round, reducing their stakes.

​The funding is done through Tata Capital Healthcare Fund II (TCHF II), the healthcare focused private equity fund of Tata Capital. About 90% of the funding will be for growth and 10% will provide exit to certain angel investors. Founded by nephrologists Jatin Kothari and Viswanath Billa, AKC has raised funds from founders and angel investors.

The US-based Bessemer Venture Partners (BVP) and the World Bank's lending arm International Finance Corporation (IFC) are exploring the sale of about 30% stake in NephroPlus, said multiple people aware of the development. Bessemer and IFC will exit fully by selling about 30% stake together. However, the largest shareholder, Investcorp, is yet to decide on offloading its stake, added sources. Bahrain-based Investcorp owns about 40% stake in NephroPlus.